Treatment Trials

4 Clinical Trials for Various Conditions

Focus your search

      RECRUITING
      An Extension Study to Assess Long-Term Safety of Eplontersen in Adults With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)
      Description

      The purpose of this study is to evaluate the safety and tolerability of extended dosing with eplontersen in participants with ATTR-CM.

      Conditions
      Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)
      Talk to us
      ACTIVE_NOT_RECRUITING
      CARDIO-TTRansform: A Study to Evaluate the Efficacy and Safety of Eplontersen (Formerly Known as ION-682884, IONIS-TTR-LRx and AKCEA-TTR-LRx) in Participants With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)
      Description

      To evaluate the efficacy of eplontersen compared to placebo in participants with ATTR-CM receiving available standard of care (SoC). For more information, please visit https://www.cardio-ttransform.com.

      Conditions
      Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)
      Talk to us
      ACTIVE_NOT_RECRUITING
      The CARDIO-TTRansform Scintigraphy Sub-study
      Description

      The purpose of this study is to examine the changes in amyloid myocardial burden in a subset of the population participating in the ION682884-CS2 (NCT04136171) study, up to 150 participants, after treatment with eplontersen or placebo based on scintigraphy scans performed at Week 140 using the Perugini grade score method.

      Conditions
      Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)
      Talk to us
      ACTIVE_NOT_RECRUITING
      CARDIO-TTRansform Magnetic Resonance Imaging (MRI) Sub-study
      Description

      The main purpose of this study is to measure the amyloid burden, defined as extracellular volume (ECV) assessed by Magnetic Resonance Imaging (MRI) over time in a subset of up to 150 participants enrolled in ION-682884-CS2 (NCT04136171).

      Conditions
      Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)
      Talk to us